



Acute Myeloid Leukemia: From Pathophysiology to Novel Therapeutic Approaches

Guest Editors:

Prof. Dr. Rotraud Wieser

Clinic of Medicine I, and
Comprehensive Cancer Center,
Medical University of Vienna,
Vienna, Austria

Dr. Giorgia Simonetti

IRCCS Istituto Romagnolo per lo
Studio dei Tumori (IRST) “Dino
Amadori”, Meldola, FC, Italy

Dr. Felicetto Ferrara

Dipartimento Onco-ematologico
e pneumoematologico, Azienda
Ospedaliera Di Rilievo Nazionale
Antonio Cardarelli, Naples, Italy

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editors

Dear Colleagues,

This Special Issue, entitled "Acute Myeloid Leukemia: From Pathophysiology to Novel Therapeutic Approaches", will mainly focus on understanding the factors that drive tumor progression and will assess the introduction of selective pathway inhibitors that tackle AML progression.

The outcome for patients with AML is improving as a result of combined efforts in academic and industrial research that introduced several new therapies, some of which are specifically addressed toward the inhibition of pathways involved in leukemogenesis.

We invite authors to submit original research and review articles that focus on the pathophysiology and new therapeutic strategies for AML. Potential topics include, but are not limited to:

- Molecular pathogenesis of AML
- Prognostic stratification
- The role of MRD
- New agents for AML
- New immunotherapeutic approaches
- The current role of allogeneic stem cell transplantation

Dr. Felicetto Ferrara
Guest Editor



mdpi.com/si/42371

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)